A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (which will be the dose
recommended for a Phase 2 study), safety, tolerability and pharmacokinetic profile (study of
movement of the drug within the body, including absorption and distribution) of the study
drug, BNC101 when administered intravenously as a single agent or in combination with
chemotherapy in patients with metastatic colorectal cancer who have failed at least 1 or 2
lines of chemotherapy.